Dermatology CPT Codes: Billing Reference for Skin, Lesion, and Procedure Coding

Dermatology is one of the most procedure-intensive specialties in medicine. A single dermatologist performing a full clinic day might conduct 30-40 encounters involving skin examinations, biopsies, destructions of premalignant and malignant lesions, excisions at various margins, cryosurgery, and phototherapy — all requiring precise code selection based on lesion type, size, technique, anatomical location, and pathological classification. The coding permutations in dermatology outnumber those in most other specialties by an order of magnitude.

This complexity creates a billing environment where systematic coding errors are both common and expensive. A practice that routinely bills shave removals (11300-series) when tangential biopsies (11102) are documented loses $30-$60 per procedure. A practice that fails to correctly measure and report excised diameter on lesion excisions underbills every specimen. A practice that does not properly report multiple destruction sessions in a single visit leaves 15-25% of procedural revenue on the table.

This guide covers the complete CPT code landscape for dermatology — E/M coding, destruction, excision, biopsy, Mohs surgery, phototherapy, and the modifier logic that binds it all together.

E/M Coding for Dermatology

Office/Outpatient Visit Codes

Dermatology-specific E/M challenges:

• Procedure-heavy encounters: The majority of dermatology encounters involve at least one procedure. When a separately identifiable E/M service is performed (beyond the decision to perform the procedure), modifier -25 must be appended. The documentation must support that the E/M addressed concerns separate from the procedural decision.
• Full-body skin exam complexity: A comprehensive skin cancer screening that identifies multiple suspicious lesions requiring biopsy involves significant medical decision-making. The exam itself — evaluating dozens of lesions against dermoscopic criteria, assessing patient history and risk factors, and determining which lesions warrant biopsy — supports moderate to high MDM (99204/99214 or 99205/99215).
• Chronic disease management: Patients managed for psoriasis, eczema, acne, or rosacea with prescription medications (biologics, immunosuppressants, isotretinoin) involve prescription drug management with side effect risk — supporting moderate MDM even when the exam is focused.

Destruction Codes (17000-17286)

Destruction codes cover the elimination of lesions by any method — cryosurgery (liquid nitrogen), electrodesiccation, curettage, laser, or chemical destruction. The code selection depends on lesion type and count.

Premalignant Lesion Destruction (Actinic Keratoses)

Critical coding rule: Report 17000 for the first actinic keratosis, then 17003 for each additional lesion (2nd through 14th). When 15 or more premalignant lesions are destroyed, report only 17004 — a flat-rate code that replaces 17000 and all units of 17003. Billing 17000 + 14 units of 17003 when you destroyed 15 or more lesions is incorrect and will be denied or recouped.

Documentation requirement: Count and document every lesion treated. "Multiple actinic keratoses destroyed with liquid nitrogen" is insufficient. The note must specify the number of lesions and their anatomical locations.

Benign Lesion Destruction

Commonly destroyed benign lesions: Seborrheic keratoses, verrucae (warts), molluscum contagiosum, dermatofibromas. Note that 17110 covers up to 14 lesions as a single flat-rate code — there is no per-lesion add-on as with actinic keratoses. For 15 or more lesions, report 17111 instead.

Malignant Lesion Destruction

Malignant destruction vs. excision: Destruction codes are appropriate when the lesion is eliminated in situ (cryodestruction, electrodesiccation and curettage). If the lesion is excised and submitted for pathological margin evaluation, use excision codes (11600-11646). The decision between destruction and excision is clinical, but the coding must match the technique actually performed.

Excision Codes (11400-11646)

Excision codes are stratified by three factors: benign vs. malignant, anatomical location, and excised diameter (lesion diameter plus the narrowest margin).

Benign Lesion Excision

Malignant Lesion Excision

Excised Diameter Measurement

The excised diameter is not the lesion diameter. It is the lesion at its greatest clinical diameter plus the narrowest margin of normal tissue excised around it. A 1.0-cm lesion excised with 2-mm margins has an excised diameter of 1.4 cm (1.0 + 0.2 + 0.2). This distinction shifts the code — and the reimbursement — to the next size tier.

Documentation requirement: The operative note must document both the clinical lesion size and the margins taken, or the excised specimen diameter. Pathology reports document the specimen size at the gross level, which can differ from the in-vivo measurement. The operative note measurement is the basis for code selection; the pathology report corroborates it.

Benign vs. malignant determination: At the time of excision, use the clinical or biopsy-confirmed diagnosis to select benign or malignant codes. If biopsy results return after the excision, the code may be adjusted — an excision initially coded as benign that pathology confirms as malignant should be recoded to the malignant series.

Biopsy Codes (11102-11107)

The biopsy code set was restructured in 2019 to distinguish biopsy technique. The initial biopsy is coded with the base code; each additional biopsy of the same technique type uses the add-on code.

Biopsy Technique Coding Rules

• Tangential (shave) biopsy (11102/11103): A horizontal or transverse incision that removes a sample including the epidermis with or without portions of the dermis. This is the most common dermatology biopsy technique.
• Punch biopsy (11104/11105): A full-thickness cylindrical sample through epidermis, dermis, and potentially subcutaneous tissue using a punch instrument.
• Incisional biopsy (11106/11107): A full-thickness sample obtained with a scalpel, removing a wedge or portion of a lesion for diagnosis. Unlike excision, the intent is diagnostic — the lesion is not fully removed.

Multiple biopsy coding: When biopsies of different techniques are performed, report each base code (11102, 11104, or 11106) for the first lesion of that technique type, and the corresponding add-on code for each additional lesion of the same type. The highest-RVU base code is listed first.

Biopsy vs. shave removal: A tangential biopsy (11102) is performed when the intent is diagnosis — the tissue is sent for pathological evaluation. A shave removal (11300-11313) is performed when the intent is therapeutic removal of a lesion. The documentation must clearly state the clinical intent. Performing a shave removal and submitting the specimen to pathology does not convert a removal into a biopsy.

Pathology Codes

Dermatology practices that perform in-house pathology (dermatopathology) also bill the pathology interpretation:

Mohs Micrographic Surgery Codes (17311-17315)

Mohs surgery is a specialized technique for removing skin cancer where the surgeon acts as both surgeon and pathologist, examining 100% of the surgical margin during the procedure.

Mohs coding rules:

• Report the first stage code (17311 or 17313) based on anatomical site.
• Each additional stage uses the add-on code (17312 or 17314).
• If any stage requires more than 5 tissue blocks, add 17315 for each additional block beyond 5.
• Wound repair after Mohs is reported separately using the appropriate repair code (intermediate or complex closure, adjacent tissue transfer, or skin graft).
• The Mohs surgeon must personally perform both the surgical excision and the pathological examination of the margins. If a separate pathologist reads the slides, Mohs codes are not appropriate — use standard excision codes.

Phototherapy and Photodynamic Therapy Codes

PDT billing: Photodynamic therapy requires both the procedure code (96567/96573/96574) and the drug supply code (J7308 for ALA or J7345 for MAL). Omitting the drug code leaves $100-$850 in revenue uncaptured per session. Document the application time, incubation period, light source, light parameters (wavelength, fluence), and treatment area.

Common Dermatology Modifier Challenges

Modifier -25: E/M with Same-Day Procedures

Dermatology is the specialty where modifier -25 is most frequently used — and most frequently audited. Nearly every encounter that involves a biopsy, excision, or destruction also involves an E/M assessment.

Compliant use: The E/M service addresses a separately identifiable clinical concern beyond the immediate procedural decision. A skin cancer screening that identifies multiple lesions, evaluates risk factors, and manages existing skin conditions represents work separate from the decision to biopsy a single lesion.

Non-compliant use: Appending modifier -25 to every procedure encounter without documentation of a separate E/M service. "Examined lesion, decided to biopsy" does not support a separate E/M.

Modifier -59: Multiple Lesion Procedures

When multiple lesions are biopsied, excised, or destroyed in the same session, modifier -59 (or the more specific X{EPSU} modifiers) may be needed to override CCI bundling edits.

• Same technique, multiple lesions: Use the base code + add-on codes (no modifier -59 needed). Example: 11102 + 11103 x3 for four tangential biopsies.
• Different techniques, same session: Report each base code. Modifier -59 on the lower-RVU base code. Example: 11102 (tangential biopsy) + 11104-59 (punch biopsy of different lesion).
• Excision and biopsy of different lesions, same session: Report the excision code and the biopsy code with modifier -59 on the biopsy.

Multiple Lesion Reporting for Destructions

A common error: billing 17000 multiple times for multiple actinic keratoses. The correct approach is 17000 for the first lesion and 17003 for each additional (up to 14), or 17004 for 15 or more. Each 17003 unit must be documented as a separate, countable lesion.

When benign lesion destructions (17110) are performed at the same session as premalignant destructions (17000 series), both can be reported — different code ranges for different lesion pathology. Modifier -59 may be needed on the secondary code to override bundling.

How QuickIntell Automates Dermatology Coding

QuickIntell's QuickCode engine handles specialty-specific CPT code selection with 99%+ accuracy, addressing the unique complexity of dermatologic procedures:

• Lesion classification: QuickCode analyzes documentation to determine benign vs. malignant vs. premalignant classification and selects the correct destruction or excision code series.
• Excised diameter calculation: Extracts lesion diameter and margin measurements from operative notes to calculate excised diameter and select the correct size-based code.
• Biopsy technique differentiation: Distinguishes tangential, punch, and incisional biopsy documentation to apply the correct 11102/11104/11106 code — and correctly structures add-on codes for multiple biopsies.
• Mohs stage counting: Tracks stage and block counts across Mohs operative notes to apply 17311-17315 with the correct add-on structure.
• Destruction count logic: Counts documented lesions and applies the correct code structure (17000+17003 vs. 17004; 17110 vs. 17111).
• Modifier -25 validation: Assesses whether the E/M documentation supports a separately identifiable service before allowing modifier -25 submission, reducing audit exposure.

For dermatology practices performing 15-25 procedures per provider per day, QuickCode eliminates the coding variability that drives $120,000-$350,000 in annual revenue leakage from undercoding, missed add-ons, and modifier errors.

---

Looking for more specialty-specific coding guidance?

Internal Links:

• CPT Codes Explained: Complete Reference Guide
• AI Medical Coding: Accuracy, Compliance, and ROI
• How to Improve First-Pass Claim Acceptance Rate
• ICD-10 and CPT Code Update Guide 2026
• Compliance Audit Survival Guide